Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer

Table 5 Univariate and multivariate analyses for progression-free survival and overall survival

Factor	Univariate analysis, HR (95%CI)	P value	Multivariate analysis, HR (95%CI)	P value
PFS
CEA (≥ 50% vs < 50% reduction)	0.45 (0.23-0.88)	0.020	0.40 (0.20-0.82)	0.012
CA19-9 (≥ 50% vs < 50% reduction)	0.50 (0.26-0.97)	0.040	0.58 (0.29-1.16)	0.123
CA72-4 (≥ 50% vs < 50% reduction)	0.48 (0.24-0.94)	0.032	0.55 (0.27-1.12)	0.098
CD4+ /CD8+ ratio (≥ 1.5 vs < 1.5)	0.42 (0.21-0.84)	0.014	0.45 (0.22-0.92)	0.028
OS
CEA (≥ 50% vs < 50% reduction)	0.52 (0.25-1.08)	0.080	0.60 (0.28-1.30)	0.197
CA19-9 (≥ 50% vs < 50% reduction)	0.55 (0.27-1.13)	0.103	0.70 (0.33-1.50)	0.361
CA72-4 (≥ 50% vs < 50% reduction)	0.43 (0.20-0.92)	0.030	0.38 (0.17-0.85)	0.018
CD4+ /CD8+ ratio (≥ 1.5 vs < 1.5)	0.40 (0.18-0.87)	0.021	0.42 (0.19-0.93)	0.033

PFS: Progression-free survival; OS: Overall survival; HR: Hazard ratio; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; CA72-4: Cancer antigen 72-4.